(Q53315209)

13 May 2018

title

Pros and cons for the development of new antiepileptic drugs. (English)

1 reference

13 May 2018

author

Matthew C. Walker

series ordinal

2

1 reference

13 May 2018

author name string

Meir Bialer

series ordinal

1

1 reference

13 May 2018

Josemir W Sander

series ordinal

3

1 reference

13 May 2018

publication date

1 January 2002

1 reference

13 May 2018

published in

CNS Drugs

1 reference

13 May 2018

volume

16

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

285-289

1 reference

13 May 2018

https://scigraph.springernature.com/pub.10.2165/00023210-200216050-00001

exact match

0 references

cites work

Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?

1 reference

12 December 2020

Some aspects of prognosis in the epilepsies: a review

1 reference

12 December 2020

Do new antiepileptic drugs justify their expense?

1 reference

12 December 2020

Epidemiology of the epilepsies

1 reference

12 December 2020

Epilepsy in developing countries: a review of epidemiological, sociocultural, and treatment aspects

1 reference

12 December 2020

Prophylactic antiepileptic agents after head injury: a systematic review

1 reference

12 December 2020

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures

1 reference

12 December 2020

Neurocysticercosis and epilepsy in developing countries.

1 reference

12 December 2020

Comprehensive primary health care antiepileptic drug treatment programme in rural and semi-urban Kenya. ICBERG (International Community-based Epilepsy Research Group)

1 reference

12 December 2020

Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs

1 reference

12 December 2020

The Long-Term Use of Gabapentin, Lamotrigine, and Vigabatrin in Patients with Chronic Epilepsy

1 reference

12 December 2020

New drugs: which should be included in the formulary? Epilepsy: all new drugs should be included

1 reference

12 December 2020

New antiepileptic drugs: the cost of innovation

1 reference

12 December 2020

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

1 reference

12 December 2020

A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy.

1 reference

12 December 2020

Early identification of refractory epilepsy

1 reference

12 December 2020

Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group).

1 reference

12 December 2020

Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).

1 reference

12 December 2020

A randomized, controlled trial of surgery for temporal-lobe epilepsy

1 reference

12 December 2020

Restrictions on the availability of antiepileptic drugs

1 reference

12 December 2020

Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis

1 reference

12 December 2020

Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries.

1 reference

12 December 2020

Do anticonvulsants alter the natural course of epilepsy? Treatment should be started as early as possible

1 reference

12 December 2020

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

1 reference

12 December 2020

10.2165/00023210-200216050-00001

Identifiers

DOI

1 reference

13 May 2018

Dimensions Publication ID

1045717502

0 references

Fatcat ID

release_4qze6gaatffe7npcrfouj7lgoy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4qze6gaatffe7npcrfouj7lgoy

24 November 2022

mapped directly with Wikidata item

1 reference

13 May 2018